Drug regulation and licensing (and the patents that claim active pharmaceutical ingredients) are based on
accuracy, including accurate descriptions of the molecule, how it is formulated and (to the extent it is understood) how it works. But what happens when
there is an error?
DDNews speaks with Bill Barbo, senior vice president of global sales and marketing for Charles River Laboratories, about such things as his company’s
acquisition of WIL Research and the role Charles River is playing in advancing immunotherapy research
journals aren't featuring as many basic science articles as they once did, and we should all be worried about that and what it bodes for precision medicine
efforts and perhaps drug discovery and development more generally, too.
The annual meeting of the AACR is coming up fast, and that has cancer on our minds and those of a lot
of other people, especially drug discovery and development folks. Find out what’s in store for the March issue on the cancer front and some of the activities
surrounding oncology right now.